Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases
Clinical trial NCT04967417 · COMPLETED
Trial details
- NCT number
- NCT04967417
- Sponsor
- Samsung Medical Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-26
- Primary completion
- 2024-06-30
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.